Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.58 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.54 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.52 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.50 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.50 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362202 | 1.00 | HTR1A (0.58) | HTR1AADRA1DADRA1AADRA1BTLR8 | |
| SCHEMBL31464495 | 0.87 | DYRK1A (0.53) | HTR1AADRA1DADRA1AADRA1BTLR8 | |
| SCHEMBL29729443 | 0.86 | LMNA (0.58) | HTR1AADRA1DADRA1AADRA1BGAK | |
| SCHEMBL282245 | 0.86 | LMNA (0.58) | HTR1AADRA1DADRA1AADRA1BGAK | |
| SCHEMBL19633702 | 0.85 | TLR8 (0.48) | HTR1AADRA1DADRA1AADRA1BTLR8 | |
| SCHEMBL2174254 | 0.83 | GRM4 (0.47) | HTR1AADRA1DADRA1AADRA1BFERMT2 | |
| SCHEMBL1894839 | 0.82 | GRM4 (0.50) | HTR1AADRA1DADRA1AADRA1BTLR8 | |
| SCHEMBL8145365 | 0.81 | HTR1A (0.61) | HTR1AADRA1DADRA1AADRA1BTLR8 | |
| SCHEMBL27968960 | 0.81 | FGFR1 (0.41) | HTR1AADRA1DADRA1AADRA1BTLR8 | |
| SCHEMBL16134905 | 0.80 | SMYD3 (0.46) | HTR1AADRA1DADRA1AADRA1BTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084779-A | 4-Substituted quinoline amino acid conjugate and preparation method and application thereof | 天津科技大学 | 2024-05-28 | — | — | CN | claimed |
| EP-3941459-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-20250360145-A1 | CSF-1R INHIBITORS AND USES THEREOF | MYROBALAN THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-25 | — | — | US | disclosed |
| CN-118852001-B | Bridged biquinoline compound and preparation method and application thereof | 中山大学 | 2025-05-20 | — | — | CN | disclosed |
| EP-4539933-A1 | CSF-1R INHIBITORS AND USES THEREOF | Myrobalan Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12281079-B2 | Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| CN-119790038-A | CSF-1R inhibitors and uses thereof | 迈巴制药公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-113924092-B | Quinoline and quinazoline compounds and methods of use thereof | 斯汀格瑞治疗股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001068186-A2 | USE OF CYANOQUINOLINES FOR TREATING OR INHIBITING COLONIC POLYPS | AMERICAN CYANAMID COMPANY (US) | 2001-09-20 | — | — | WO | disclosed |
| CN-1304936-A | Quinoline-4-radical derivative II | HOFFMANN LA BOCHE & CO AG F (CH) | 2001-07-25 | — | — | CN | disclosed |
| EP-1090917-A1 | Quinolin-4-yl derivatives and their use as NMDA-receptor subtype blockers | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| CN-1290698-A | Quinoline-4-base deviative I | HOFFMANN LA ROCHE (CH) | 2001-04-11 | — | — | CN | disclosed |
| EP-1088818-A1 | Quinolin-4-yl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-04 | — | — | EP | disclosed |
| EP-0973746-A1 | SUBSTITUTED 3-CYANO QUINOLINES | American Cyanamid Company (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1998043960-A1 | SUBSTITUTED 3-CYANO QUINOLINES | AMERICAN CYANAMID COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |
| US-5773449-A | BACTERICIDES FOR HELICOBACTER | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1998-06-30 | — | — | US | disclosed |
| EP-0786454-A1 | THIOQUINOLONE DERIVATIVE | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 1997-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | HTR1A 517/4885ADRA1D 225/4885ADRA1A 189/4885 |
| US-20250360145-A1 | CSF-1R INHIBITORS AND USES THEREOF | CSF1R, CSF3R, IL1RN | HTR1A 3696/4885ADRA1D 1714/4885ADRA1A 2171/4885 |
| US-12281079-B2 | Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer | AVPR2, AVPR1A, VHL | HTR1A 1853/4885ADRA1D 889/4885ADRA1A 666/4885 |
| US-12479826-B2 | Pyridazinyl amino derivatives as ALK5 inhibitors | ALK, TGFBR1, ACVR1 | HTR1A 2440/4885ADRA1D 337/4885ADRA1A 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.